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Abstract  1 
Background 2 
Low 25(OH) vitamin D status is associated with increased cardiovascular events in 3 
epidemiological studies.  4 
 5 
Objective 6 
The aim was to assess if vitamin D supplementation reduces cardiac failure, myocardial 7 
infarction (MI) and stroke, through analysis of the RECORD randomized controlled trial (RCT), 8 
and systematic review and meta-analysis. 9 
 10 
Design 11 
Two analyses were undertaken. Firstly, a trial analysis. RECORD was a factorial RCT comparing 12 
vitamin D3 (800IU daily), calcium (1,000mg daily), vitamin D plus calcium and placebo. 13 
Cardiovascular events were collected throughout the trial and three years’ post-trial follow-14 
up. Data were analysed using Cox regression.  15 
Secondly, a systematic review. MEDLINE, EMBASE, CENTRAL, conference abstracts and on-16 
going trials were searched for RCTs evaluating vitamin D from 1980 to 2013.  RCTs with at 17 
least one year of follow-up and participants’ mean/median age of 60 years or older were 18 
included. Meta-analyses were based on a Bayesian fixed-effects model using a 19 
complementary log-log link function to account for varying length of follow-up. 20 
 21 
Results 22 
Trial analysis showed that for the 5292 participants in the RECORD trial the hazard ratios for 23 





HR 0.75 (95%CI 0.58, 0.97), HR 0.97 (95%CI 0.75,1.26), and HR 1.06 (95%CI 0.8, 1.32) 25 
respectively. 26 
Twenty-one studies met the inclusion criteria for the systematic review (n=13,033). Estimated 27 
hazard ratios (credible intervals) for vitamin D compared to placebo or control for on-study 28 
events for cardiac failure, myocardial infarction and stroke were HR 0.82 (Crl 0.58, 1.15), HR 29 
0.96 (Crl 0.83, 1.10) and HR 1.07 (Crl 0.91, 1.29) respectively. 30 
 31 
Conclusion 32 
Vitamin D supplementation might protect against cardiac failure in older people, but does not 33 
appear to protect against MI or stroke. 34 
 35 






Low 25-hydroxyvitamin D [25(OH)D] status has been associated with cardiovascular disease in 38 
epidemiological studies (1). Lower 25(OH)D levels are seen in patients with higher blood 39 
pressure, metabolic syndrome, heart failure and stroke than in patients without these 40 
disorders (1). Suggested pathophysiological mechanisms by which vitamin D deficiency could 41 
lead to cardiovascular disease, including heart failure, are overactivity of the renin-42 
angiotensin-aldosterone system (RAAS); endothelial dysfunction; direct effects on calcium 43 
flux leading to decreased myocyte contractility; hyperparathyroidism, which is associated 44 
with left ventricular hypertrophy; promotion of chronic inflammation; and increased risk of 45 
metabolic syndrome and type 2 diabetes (1). The causality of these relationships is debated 46 
however, and the quality of the available studies criticised (2). Known risk factors for 47 
cardiovascular disease, including smoking, obesity, inactivity (thus reduced sun exposure) and 48 
advanced age, are associated with lower 25(OH)D, making dissection of the causal role of low 49 
25(OH)D status in cardiovascular disease difficult. Finally, recent evidence suggests that 50 
25(OH)D may be a negative acute-phase reactant, thus chronic disease may lead to low 51 
25(OH)D, even in the presymptomatic phases of cardiovascular disease (3). 52 
 53 
There have been several previous systematic reviews evaluating vitamin D supplementation 54 
and cardiovascular outcomes, but these reviews have not focussed on cardiac failure (4-8), an 55 
area of growing interest (9-10). The most recent reviews found no effect on cardiovascular 56 
mortality (RR 0.98, 95%CI 0.90 to 1.07) (4) or on the incidence of myocardial infarction (MI) 57 
(RR 1.02 95%CI 0.93 to 1.13) or stroke (RR 1.05 95%CI 0.88 to 1.25) (6). Wang and colleagues 58 
found a statistically nonsignificant reduction in cardiovascular disease with moderate to high 59 





examined the effect of supplementation on chronic heart failure; an area of growing interest 61 
(9,10). 62 
Previous systematic reviews used a narrow search strategy by including cardiovascular terms, 63 
and included vitamin D plus calcium versus placebo or control RCTs, wrongly assuming no 64 
effect of calcium on cardiovascular disease (11,12), nor sought unpublished data. We 65 
undertook an extensive search for new published and unpublished trial data using a broad 66 
search strategy, and included unpublished data from the RECORD trial for the secondary 67 
prevention of fractures (13). 68 






RECORD Trial 71 
Study design and participants 72 
Full details of the RECORD study (ISRCTN 51647438) have been published (13). This was a 73 
factorial trial that randomized 5,292 participants with previous fracture to oral vitamin D3 74 
(800 IU daily) plus calcium (1,000 mg daily as calcium carbonate), vitamin D3 alone, calcium 75 
alone or placebo. Participants were recruited between Feb 1, 1999 and Mar 31, 2002.  The 76 
primary outcome was low-trauma fracture. Major inclusion criteria were age 70 years or over 77 
and fracture in the past ten years. Exclusion criteria included cognitive impairment, daily 78 
supplement intake of vitamin D or calcium (maximum 200 IU and 500 mg respectively) and 79 
bone altering medications. Ethics approval was obtained from the Multicentre Research 80 
Ethics Committee for Scotland and from the local research ethics committee of each hospital, 81 
and participants gave written informed consent. 82 
 83 
Randomization and masking 84 
Participants were randomized by a central computerised system that minimised by age 85 
(below 80 years or 80 years and above), sex, time since initial fracture (three months and less 86 
or more than three months) and type of fracture  (proximal femur, distal forearm, clinical 87 
vertebral or other). Participants were allocated to daily doses of vitamin D3 800 IU, calcium 88 
1000 mg, combined vitamin D3 plus calcium or placebo. Allocation remained concealed until 89 
final analysis. Tablets were posted to participants every four months. Participants and 90 







Deaths attributed to cardiovascular or cerebrovascular disease were pre-specified as 94 
outcomes in the main trial protocol (http://www.thelancet.com/protocol-reviews/02PRT-35),. 95 
In addition, cardiovascular outcome data were collected from questionnaires, hospital and 96 
family doctors’ reports, nominated friends or family, as well as death certificates. After trial 97 
closeout, data were only collected from the main cause of death from death registrations, 98 
provided by the General Register Office for Scotland for all UK participants; these data were 99 
collected independently of the trial as part of routine national statistics. On-study data 100 
collected during the RECORD trial were adjudicated by researchers independent from the 101 
trial, with advice from cardiologists. 102 
 103 
All participants alive at trial closure were included in a three year ‘off-study’ post-intervention 104 
follow-up period.  105 
 106 
Three pre-specified outcomes comparing vitamin D (with or without calcium) with no vitamin 107 
D (with or without calcium) supplementation as per factorial trial design from both on-study 108 
(24 to 62 months follow up) and off-study periods (three years after trial closure) were 109 
assessed: time to first cardiac failure, time to first MI, time to first stroke, and time to first 110 
composite outcome of cardiac failure, MI or stroke. Inclusion of the off-study period was 111 
justified because it allowed the potential lag effect of vitamin D to be examined, where 112 
remodelling could occur several years before clinically overt heart failure. 113 
 114 
The following definitions were used; 115 
- cardiac failure –  “heart failure”, “pulmonary oedema” or synonymous terms, or any of 116 





- myocardial infarction – “myocardial infarction” or “heart attack”, or ICD-9 code 410 118 
- stroke - “stroke”, “cerebral infarction”, “intracerebral hemorrhage”, “subarachnoid 119 
hemorrhage”, or “cerebrovascular accident”, or any of the ICD-9 codes 430, 431, 433, 120 
434 121 
- composite – cardiac failure, myocardial infarction or stroke, as defined above  122 
 123 
Statistical analysis 124 
RECORD trial outcomes were analysed in a time-to–event framework using Cox proportional 125 
hazards regression models. The potential for any effect modification due to an interaction 126 
with calcium was explored in subgroup analysis and summarised graphically using a forest 127 
plot presenting the treatment effect in the calcium subgroup, the no-calcium subgroup and 128 
the interaction effect (which tests the difference between these subgroups). Sensitivity 129 
analysis explored the effects of compliance with treatment allocation. A post hoc analysis of 130 
fatal events was undertaken by replicating the primary analysis. All estimates of treatment 131 
effects are presented as hazard ratios (HR) and 95% confidence intervals. Further details of 132 
the regression model and compliance sensitivity analysis can be found in supplementary 133 
material. 134 
 135 
Systematic review and meta-analyses 136 
Data sources and searches 137 
A systematic search for randomized trials of vitamin D supplementation was undertaken. 138 
Published studies were identified from MEDLINE (January 2005 to February 2013), EMBASE 139 
(January 2006 to February 2013) and CENTRAL (January 1980 to February 2013). MEDLINE 140 





databases. The references of included studies and published systematic reviews were 142 
screened. Grey literature was identified from hand searching conference abstracts of the 143 
American Society for Bone and Mineral Research 2007 to 2012. The International Clinical 144 
Trials Registry Platform was searched for unpublished and on-going trials.  145 
 146 
Study selection 147 
Only RCTs including participants with a mean/median age of equal to or more than 60 years 148 
(older age reflecting higher risk of vitamin D deficiency) and at least one-year follow up were 149 
included. Any vitamin D or vitamin D analogue intervention was eligible, as we were looking 150 
for a class effect. Co-administration with other medications, such as calcium, was allowed 151 
provided that the comparator group received the same medication. There were no language 152 
restrictions. Studies assessing vitamin D supplementation in participants selected solely on 153 
the basis of renal impairment (estimated glomerular filtration rate, eGFR, 60ml/min/1.73m2), 154 
steroid-induced osteoporosis or psoriasis were excluded.  155 
 156 
To locate unpublished data authors were contacted for studies that met the inclusion criteria 157 
but did not report cardiovascular outcomes, or were completed but unpublished. Authors 158 
were also contacted to resolve any uncertainties in the published data. 159 
 160 
Data extraction and quality assessment 161 
Data were extracted by one author, double-checked by a second reviewer and discrepancies 162 
resolved through discussion. Data were extracted per patient rather than per event. Risk of 163 






Data synthesis and analysis 166 
The RCTs included in the study reported outcomes at varying lengths of follow-up. Standard 167 
meta-analysis ignores variation in follow-up that may be sub-optimal when longer follow-up 168 
results in more events, as is the case here. Therefore a Bayesian fixed-effects model using a 169 
complementary log-log link function to account for varying length of follow-up was used. 170 
Further details can be found in supplementary information. Results are presented as hazard 171 
ratios and 95% credible intervals, based on fixed effects models. Random effects models were 172 
also run and compared to the fixed models using the residual deviance. Traditional random 173 
effects meta-analysis models were run in Stata using only the proportions of participants 174 
experiencing events. These are presented as risk ratios and 95% confidence intervals for 175 
comparison. Forest plots are presented for illustrative purposes. All analyses, both for the 176 





Results  178 
RECORD Trial 179 
Full details of the recruitment and participant flow for the RECORD trial are published 180 
elsewhere (13). There were 2,649 participants randomized to vitamin D and 2,643 to no 181 
vitamin D. The groups were similar at baseline (Table 1). The mean age was 77.5 years (SD 182 
5.6). Most participants were white and female. Only a small number of participants had 183 
diabetes or were smokers. In the vitamin D group 438 participants died during the on-study 184 
period compared with 460 in the no vitamin D group. Median time from randomization to 185 
final post-trial follow up was 6.2 years in the vitamin D group (IQR 5.1 to 7.0) and 6.2 years in 186 
the no vitamin D group (IQR 4.9 to 7.0).  187 
 188 
Descriptive information on outcomes for the entire follow-up period and estimated treatment 189 
effects are presented in Table 2 and Supplementary Table 1. The risk of first cardiac failure 190 
was lower in the vitamin D group compared to no vitamin D, adjusted HR 0.75 (95%CI 0.58, 191 
0.97; p = 0.027) (Table 2 and Supplementary Figure 1). There was no evidence of a difference 192 
in risk for MI (HR 0.97 95%CI 0.75, 1.26; p= 0.84), stroke (HR 1.06, 95% CI 0.85, 1.32; p = 0.61) 193 
or the composite outcome (HR 0.92, 95%CI 0.80, 1.08; p = 0.32). 194 
 195 
Risk of fatal cardiac failure was lower in the vitamin D group compared to no vitamin D 196 
(adjusted HR 0.70, 95%CI 0.53, 0.91; p = 0.009) but risk of fatal events was not lower for other 197 
outcomes (Table 2).  198 
  199 
According to the pre-specified definition of adherence, 2,268 (42.9%) participants were 200 





group (42.0%).  For the composite outcome the hazard ratio adjusted for adherence was 0.99 202 
(95%CI 0.59, 2.31). This was similar to the analysis that was not adjusted for adherence (HR 203 
0.92, 95%CI 0.80, 1.08).  204 
 205 
Interaction between vitamin D and calcium was found to be small, but there was considerable 206 
uncertainty (Supplementary Figure 2). 207 
 208 
Systematic review and meta-analysis 209 
Literature searching identified 8,907 records (Supplementary Figure 3). The full texts of 197 210 
articles were assessed and 132 articles were excluded. The commonest reason for study 211 
exclusion was comparison of calcium plus vitamin D versus placebo. Fifty-six studies met the 212 
inclusion criteria.  Eight studies reported suitable cardiovascular outcomes in the published 213 
report (16-23). Authors of eleven studies provided supplementary data on cardiovascular 214 
events (24-33). Unpublished data from Avenell 2004 (34) were available locally from the 215 
Health Services Research Unit, University of Aberdeen. For consistency with the other trials, 216 
on-study data from the analysis of the RECORD study was included in the primary meta-217 
analysis. In total, 21 studies met the inclusion criteria for meta-analysis. Three studies did not 218 
report any event in either arm and therefore did not contribute to the meta-analysis (23, 24, 219 
32). 220 
 221 
Characteristics of included studies are shown in Table 3.  Thirteen studies included only 222 
female participants, one study only male and the remaining both. Eight studies included only 223 
participants at higher risk of fracture, i.e. previous fracture, osteoporosis or osteopenia. 224 





yearly; expressed as dose per day, doses ranged from 800 IU to 4000 IU. Calcitriol was used in 226 
four studies and doses ranged from 0.25 µg to 0.50 µg per day and two studies included a 227 
dose escalation protocol. Ergocalciferol was used in two studies. In five studies a vitamin D 228 
analogue was used (doxercalciferol, alfacalcidol, 2MD, or ED71). In 13 studies the follow-up 229 
period was 12 months. The follow-up of the remaining studies ranged from a median of 17.6 230 
months to 6.2 years. 231 
 232 
Studies were generally of low or unclear risk of bias (Supplementary Table 2). Xia 2009 and 233 
Avenell 2004 were open label studies (27, 34). 234 
 235 
In total 13,033 participants were included. Mean ages ranged from 61 years to 77 years 236 
(Supplementary Table 3) Baseline 25(OH)D was recorded in eleven studies, ranging from 24 237 
to 80 nmol/l.  238 
 239 
Vitamin D did not significantly reduce the risk of cardiac failure compared with no vitamin D 240 
(68 vs 80 events, HR 0.82, credible interval, CrI 0.58, 1.15, Table 4). There was no statistically 241 
significant difference in MI or stroke events between vitamin D and no vitamin D (320 vs 334 242 
events, HR 0.96, CrI 0.83, 1.10; 251 vs 226 events, HR 1.07, CrI 0.91, 1.29, respectively). There 243 
was low statistical heterogeneity throughout. Figures 1, 2 and 3 shows forest plots produced 244 
by the traditional random effects meta-analysis for illustrative purposes. 245 
 246 
In a post hoc sensitivity analysis, only trials evaluating cholecalciferol or ergocalciferol were 247 





CrI 0.82, 1.10; stroke HR 1.08, CrI 0.91, 1.29). There were no trials of vitamin D analogues 249 
which provided data on cardiac failure. 250 
 251 
Funnel plot inspections did not suggest publication bias. 252 
 253 
In the sensitivity analysis, including off-study events from the RECORD trial, risk of cardiac 254 
failure event was statistically significantly lower in vitamin D compared to the no vitamin D 255 
group (overall HR 0.79, CrI 0.59, 0.99). No statistically significant differences were found for 256 






Analysis of the whole follow-up period of the RECORD trial showed a statistically significant, 259 
clinically important reduced risk of cardiac failure events with vitamin D, but that vitamin D 260 
had no significant effect on MI, stroke or the composite outcome. Meta-analysis found that 261 
vitamin D did not reduce the risk of cardiac failure during the on-study periods in the trials, 262 
but inclusion of the RECORD off-study events generated a statistically significant effect. No 263 
statistically significant difference was found in the meta-analysis for MI or stroke. There was 264 
no indication of adverse effects of vitamin D on cardiovascular disease. 265 
What do these results mean? 266 
The results suggest that there is insufficient evidence to support vitamin D supplementation 267 
for the reduction of cardiovascular events, but raise the possibility that it might impact on 268 
heart failure. This might occur by preventing the development of heart failure, or mitigating 269 
its progression. The key drivers for heart failure in older patients are ischemic heart disease 270 
and hypertension (35), but the lack of effect of vitamin D on MI does not support this 271 
mechanism. This may suggest that vitamin D affects the chronic pathogenesis of heart failure.  272 
A systematic review of trials of vitamin D supplementation found that there may be a 273 
beneficial effect on blood pressure (36); this may be of particular significance in this study as 274 
hypertension is a common cause of heart failure in older women (37).  275 
 276 
If vitamin D does not prevent the onset of heart failure, it could mitigate the severity of the 277 
syndrome once established. Existing trial data are contradictory. Vitamin D supplements 278 
improved echocardiographic markers of heart failure and pro-inflammatory cytokines in a RCT 279 
in Egyptian infants with 25(OH)D of 35 nmol/L (38). In a RCT of adults with cardiac failure 280 





cytokines, but had no significant effect on echocardiographic parameters or N-terminal 282 
propeptide of brain natriuretic peptide (BNP). In a small, short-term trial Witham and 283 
colleagues found that vitamin D supplementation (100,000 IU ergocalciferol every 10 weeks) 284 
improved BNP compared to placebo, but had no effect on symptoms, exercise capacity or 285 
quality of life in older patients with heart failure despite low baseline 25(OH)D (mean 21 286 
nmol/L)(40). 287 
 288 
Vitamin D supplementation reduces parathyroid hormone (PTH), which is known to be 289 
vasculotoxic and associated with left ventricular hypertrophy (1). In a cohort study (n=864), 290 
Hagstrōm and colleagues found that high PTH levels were associated with increased cardiac 291 
failure hospitalisations (HR for 1-SD increase of PTH, 1.41, 95% CI 1.12, 1.77) (41). 292 
 293 
Vitamin D could reduce cardiac failure through the RAAS system.(42) In a very large cohort of 294 
individuals without heart failure, low vitamin D status was associated with increased RAAS 295 
activation (43). However, in randomised trials Witham and colleagues (40) and Boxer and 296 
colleagues (44) found no significant effect on RAAS in patients with heart failure, perhaps in 297 
part due to the high prevalence of RAAS system blocker use in heart failure patients. The 298 
mechanism is not clear, postulated mechanisms include upregulation of vascular endothelial 299 
growth factor, and mediation through calcium myocyte handling with improved cardiac 300 
muscle strength (1). It was not possible to explore J or U shaped associations between 301 
outcomes and 25(OH)D levels because of the limited 25(OH)D data in RECORD. 302 
Context of these results 303 
Previous systematic reviews (4, 6, 8) of RCTs of vitamin D on cardiovascular endpoints failed 304 





searching and failure to obtain unpublished data. Some reviews included trials which 306 
compared calcium and vitamin D versus placebo or control, as well as trials of vitamin D 307 
alone, which is problematic because calcium has been found to increase the risk of 308 
cardiovascular events (11,12). In the Women’s Health Initiative (WHI) trial (45), co-309 
administered calcium and vitamin D had no effect on CHF in the entire cohort, but might 310 
reduce the risk of CHF in women at low risk of cardiovascular disease, but not in those at high 311 
risk (46).  312 
 313 
A Cochrane review of RCTs evaluating vitamin D and overall mortality, undertook a subgroup 314 
analysis of cardiovascular mortality and found no difference, although overall mortality was 315 
slightly reduced (RR 0.97, 95% CI 0.94 to 0.99). (4). Given the findings of this review we decided 316 
to test the robustness of the RECORD Trial results to a post-hoc sensitivity analysis to explore 317 
the potential influence of death from all other causes within a competing risks 318 
framework.  These results (not presented) were practically identical to the results in Table 2 319 
and are robust to death from other causes. Similarly, Elamin and colleagues in a meta-analysis 320 
including randomised controlled trials, found no difference for MI or stroke (6). Wang and 321 
colleagues, undertook a meta-analysis of two trials and found a non-statistically significant 322 
reduction in cardiovascular outcomes (8). In a trial sequential meta-analysis, Bolland and 323 
colleagues found that vitamin D did not reduce skeletal or non-skeletal outcomes by more 324 
than 15%.(47) 325 
Strengths and weaknesses 326 
RECORD was a trial of secondary prevention of fractures. Osteoporosis has been associated 327 
with an increased risk of cardiovascular disease (48), so the participants in RECORD may have 328 





participants were mainly women and only 8% were diabetic. Although cardiovascular 330 
outcomes were prespecified, RECORD was not designed as a cardiovascular trial and event 331 
were no verified against participants’ medical records. Compliance with tablets was poor 332 
reducing the examination of efficacy, but this reflects likely compliance in clinical practice. 333 
Data after trial close out were only collected from death certificates, so non-fatal events were 334 
missed. However, the longer follow-up did allow the potential lag effect of vitamin D to be 335 
examined. We used a robust search strategy for the systematic review. Studies were found 336 
which reported cardiovascular events in the full text, but not abstract or title in databases. 337 
Unpublished data from 12 trials were included. However, the method of collecting 338 
cardiovascular data varied between studies. Meta-analysis was driven by two studies (13,21). 339 
Therefore results are sensitive to the population and vitamin D dose of these studies.  340 
Future research 341 
Further mechanistic studies are really needed to explore the mechanisms by which vitamin D 342 
could influence the development or progression of heart failure in high risk groups. 343 
Sufficiently powered, high quality RCTs are needed to investigate the relationship between 344 
cardiovascular disease and vitamin D. The VITAL trial randomizes 20,000 healthy participants 345 
to cholecalciferol 2,000 IU/d or placebo for five years with primary outcomes including MI, 346 
stroke, and death from cardiovascular disease (49).  . However, participants are allowed to 347 
take non-protocol supplements of up to 800 IU/d of vitamin D and 1g/d of calcium. The ViDA 348 
trial (http://www.anzctr.org.au/) is assessing effects of 100,000IU/month cholecalciferol on 349 
cardiovascular disease in 5100 men and women aged 50-84 years. The FIND trial 350 
(http://clinicaltrials.gov/show/NCT01463813), is examining effects of 1,600IU/d, 3,200IU/d or 351 
placebo on cardiovascular disease in 18,000 men and women 60y and over. An on-going trial ( 352 





cardiac failure to vitamin D or control and measure symptom improvement and mortality at 354 
three years. However, no studies are currently aiming to prevent heart failure in patients at 355 
high risk (e.g. MI with reduced ejection fraction). These trials are using high doses of vitamin 356 
D, though none have set vitamin D deficiency as an entry criterion.(50) 357 
 358 
In conclusion, long-term RECORD trial results demonstrate that vitamin D, compared to no 359 
vitamin D, resulted in a statistically significant reduction in cardiac failure events. In meta-360 
analysis there was evidence to suggest that vitamin D supplementation may reduce cardiac 361 
failure events in older people when these RECORD data are included, but not for on study 362 
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Tables and figures 
Table 1: RECORD baseline characteristics 
 
Variable  




Age in  years - mean (SD) 77.5 (5.6) 77.4 (5.6) 
Calcium  1,306(49.3) 1,311(49.6) 
Female  2,240 (84.6) 2,241 (84.8) 
White 2,629 (99.2) 2,623 (99.2) 
Type of enrolling  
fracture 
Proximal femur 459 (17.3) 445 (16.8) 
Distal forearm 924 (34.9) 922 (34.9) 
Clinical vertebral 4 (0.2) 4 (0.2) 
Other 1,262 (47.6) 1,272 (48.1) 
Time since enrolling 
fracture 
   
≥ 3 months 469 (17.7) 475 (18.0) 
Diabetes mellitus 208 (7.9) 212 (8.0) 
Oral hypoglycaemics 119 (4.5) 108 (4.1) 
Insulin 40 (1.5) 50 (1.9) 
Current smoker 298 (11.3) 320 (12.1) 
Ambulant in community1 2,492 (94.1) 2,487 (94.1) 
Oral steroids ≥ 7.5 mg prednisolone per day 49 (1.9) 44 (1.7) 
Cell contents are n (%) unless otherwise stated; 1able to walk outdoors unaccompanied  













HR1  (95%CI) P value 
Fatal and non-
fatal events 
Cardiac failure 102 136 0.75 (0.58, 0.97) 0.027 
MI 114 117 0.97 (0.75, 1.26) 0.84 
Stroke 160 149 1.06 (0.85, 1.32) 0.61 
Composite 
outcome 
339 363 0.92 (0.80, 1.08) 0.32 
Fatal events only 
Cardiac Failure 89 127 0.70 (0.53, 0.91) 0.009 
MI 87 88 0.99 (0.73, 1.33) 0.92 
Stroke 102 101 0.99 (0.75, 1.30) 0.94 
Composite 
outcome 
256 291 0.87 (0.73, 1.03) 0.11 
HR = hazard ratio, CI = confidence interval, MI = myocardial infarction, 1 Cox regression 
adjusted for: age (younger than 80 years or 80 years and older), sex, time since fracture 
(previous three months or longer), type of fracture (proximal femur, distal forearm, clinical 







Table 3: Study characteristics 
Study 
Country 
Participants Interventions given to all 
participants 




Postmenopausal women with 
osteoporosis aged 50 to 80 years 
Vit D 400 IU daily 
(unspecified) and calcium 
1,000 mg dietary intake  
Calcitriol 0.50 µg daily with 
dose escalation if necessary 
Placebo Bone biopsy, mineral 
& urinary 
measurements and  
radiographs  
2 years 
Attia 2008 USA 
(23) 
Men with metastatic prostate 
cancer without starting 
chemotherapy 
Docetaxel plus 
dexamethasone on cycle 
days 1, 8 & 15  








Men and women aged ≥ 70 years 
with a previous low trauma 
osteoporotic fracture 
None Oral calcium 1g daily, oral 
cholecalciferol 800 IU daily 
or both 





Postmenopausal women with 
osteopenia aged 55-80 years  
Cholecalciferol 600 IU 
daily  





Women aged 65-77 years with 
no evidence of osteopenia 
None Calcitriol 0.25 ug twice a day 
HRT alone, or HRT plus 
calcitriol  






White postmenopausal women 
aged 57 to 90 years with vitamin 
D insufficiency 
Daily calcium to maintain 
intake of 1200 to 1400 mg 
Cholecalciferol 400, 800, 
1600, 2400, 3200, 4000, or 
4800 IU once daily 







Gorai 2010 Japan 
(25) 
Postmenopausal women living in 
Japan 
None Alfacalcidol 1.0 ug daily or 
raloxifene 60 mg plus 
vitamin D daily  








Current or former smokers >50 
years with COPD  
None Cholecalciferol 100 000 IU 
monthly 





Postmenopausal women living in 
Japan 
None Alfacalcidol 1.0 ug daily or 
raloxifene 60 mg plus 
alfacalcidol daily  





Matsumoto 2005  
Japan (26) 
Postmenopausal women with 
osteoporosis over 60 years old 
Cholecalciferol 400 IU/d if 
25(OH)D < 50 nmol/l or 
with 200 IU/d if ≥ 50 
nmol/l 
ED-71 0.5, 0.75, or 1.0 ug 
daily  




Ott 89  
USA (19) 
Postmenopausal women with at 
least two compression fractures  
Calcium to maintain intake 
of 24.9 mmol/day  
Calcitriol 0.25 ug twice daily 
with dose escalation if 
needed  





Women with vitamin D 
deficiency aged 70 to 90 years 





Men and women over 70 years 
with previous low trauma 
fracture 
None Cholecalciferol 800 IU daily, 
calcium 1 g daily or both  







Women over 70 years with high 
risk of fracture 
None Cholecalciferol 500 000 IU 
once yearly  









Community-dwelling men and 
women aged 55-85 years 
None Cholecalciferol 1,600 IU plus 






Trivedi 2003 UK 
(21) 
Men and women aged 65-85 
from British doctors’ register & 
general practice register 
None Cholecalciferol 100 000 IU 
every four months  
Placebo Fracture incidence 




Men and women aged over 70 
years with BP more than 140 
mmHg systolic and 25(OH)D less 
than 75 
None Cholecalciferol 100,000 IU 
every three months 





Men and women with stable 
cardiac failure 





Postmenopausal women living in 
Scotland 
None Cholecalciferol 400 IU per 
day or 1000 IU per day 
Placebo Serum lipid profile, 






Xia 2009 China 
(27) 
Postmenopausal women over 65 
years living in China 
None Calcitrol 0.25 μg plus 
Caltrate D (calcium 600 mg 
and 125 IU cholecalciferol) 
daily  
Caltrate D alone 
(calcium 600 mg 












Women aged over 70 years 
selected from electoral register 
None Calcium 1200mg with 
ergocalciferol 1000 IU daily  
Calcium 1200mg 
with placebo 




AE = adverse event, NIH = National Institute of Health, BMD = bone mineral density, IU = international units, NR = not reported, PTH = parathyroid hormone, BP = blood 
pressure, FEV1 = forced expiratory volume in 1 second, COPD = chronic obstructive pulmonary disease, QoL = quality of life, HRT = hormone replacement therapy, ALP = 
alkaline phosphatase , ALAT= alanine aminotransferase, GGT = gamma-glutamyl transpeptidase, TSH = thyroid stimulating hormone, BALP = bone alkaline phosphatase, 





Table 4:  Meta-analysis results including on-trial only results from RECORD 
Outcome RR3 (95% CI) HR2 (95% CrI1) 
Cardiac failure 0.83 (0.60, 1.13) 0.82 (0.58, 1.15) 
MI 0.96 (0.83, 1.10) 0.96 (0.83, 1.10) 
Stroke 1.09 (0.92, 1.30) 1.07 (0.91, 1.29) 
1 CrI is credible interval 2 Calculated using traditional random effects meta-analysis methods 






Figure legend page 
 
Figure 1: Cardiac failure forest plots for illustrative purposes including on-trial only 
results from RECORD  
  
Figure 2: Stoke forest plots for illustrative purposes including on-trial only results from 
RECORD 
 
Figure 3: Myocardial infarction forest plots for illustrative purposes including on-trial only 
results from RECORD 
 
 
 
